If scientists want to boost immune cells’ ability to kill cancer cells, then vast libraries of small molecules are potentially available. A new paper shows a platform to sort through them, plus validation. One of the hits: IAP antagonist birinapant, which is already in clinical trials (coincidentally).
Uncovering more options in cancer immunotherapy
If scientists want to boost immune cells’ ability to kill cancer cells, then vast libraries of small molecules are potentially available. A new paper shows a platform to sort through them, plus validation. One of the hits: IAP antagonist birinapant, which is already in clinical trials (coincidentally).